Validation of a 24hrs nHBHA-IGRA.

<p>The effect of IL-7 on the IFN-γ secretion was analysed for 7 LTBI (panel A) and 7 control subjects (panel B). PBMC were <i>in vitro</i> incubated during 24 hrs with or without 2 µg/ml of nHBHA in the absence or presence of 5 ng/ml IL-7. The IFN-γ concentrations released in the cell culture supernatants were measured by ELISA. Box and whiskers represents the median, 25^th–75th percentiles, and the ranges of IFN-γ concentrations obtained for the included subjects. The results from the 24 hrs and the 96 hrs nHBHA-IGRA were compared for 29 immunocompetent subjects (panel C) and for 96 haemodialysis patients (panel D). PBMC were <i>in vitro</i> incubated during 24 hrs in presence of 2 µg/ml nHBHA with 5 ng/ml IL-7 or during 96 hrs in presence of 2 µg/ml nHBHA without IL-7, for 12 controls and 17 LTBI individuals (panel C, open and black circles respectively), and for haemodialysis patients (panel D). Correlations between IFN-γ concentrations released in the cell culture supernatants obtained with the two different incubation times are represented on the figure, each dot corresponding to a single subject. The values of the r Spearman correlation index are 0.792 (p<0.0001) and 0.936 (p<0.0001) on panel C and D, respectively.</p

Comparison of the different IGRA results obtained in HD patients.

<p>PBMC freshly isolated from whole blood of 135 HD patients were incubated 24hrs in presence of nHBHA (2 µg/ml) with 5 ng/ml IL-7, or 96hrs in presence of PPD (4 µg/ml) before measuring the corresponding IFN-γ concentrations released in the supernatant. The squares represent the IFN-γ concentrations (pg/ml) in response to PPD and nHBHA in QFT positive patients (Panel A, n = 45) and in QFT negative patients (Panel B, n = 90). Each square symbolizes a single patient, black and open squares representing patients originated from high and low incidence TB countries, respectively. Dotted lines indicate the positivity cut-off for each test. Percentages represent the proportion of results within the indicated quadrant among the total number of patients (n = 135).</p

Venn diagram illustrating the positive IGRAs in ESRD patients.

<p>The different IGRAs are depicted by three circles within which are included the number of positive assays. In the case of positive patients for two or three different assays, they are represented in the intersections of the circles.</p

Positive nHBHA-IGRA results in QFT positive or negative HD patients.

<p>PBMC freshly isolated from whole blood of 135 HD patients were incubated 24 hrs in presence of nHBHA (2 µg/ml) with 5 ng/ml IL-7, and the IFN-γ concentrations released in the cell cultures supernatants were measured by ELISA. Seventy-six subjects were nHBHA-IGRA positive. QFT was performed simultaneously and each dot represents a positive nHBHA-IGRA result (expressed in pg/ml) for single patient presenting either a positive QFT (QFT+ = 40) or a negative QFT (QFT− = 36). Horizontal bars represent the medians of the results.</p

Kaplan-Meier plots of the risk of disease relapse following rituximab in 31 IgG4-RD responding patients.

<p>Kaplan-Meier plots of the risk of disease relapse following rituximab in 31 IgG4-RD responding patients.</p

Kaplan-Meier plots of the risk of disease relapse following rituximab for patients with IgG4-RD RI >9 and with IgG4-RD RI ≤9 at RTX treatment.

<p>IgG4-RD RI, IgG4-related disease Responder Index.</p

Clinical, biological and radiological efficacy of RTX in 33 patients with IgG4-RD.

<p>Clinical, biological and radiological efficacy of RTX in 33 patients with IgG4-RD.</p

Hazard ratio for risk of flare: Unadjusted Cox regressions.

<p>Hazard ratio for risk of flare: Unadjusted Cox regressions.</p

Kaplan-Meier plots of the risk of disease relapse following rituximab for patients with IgG4-RD RI >9 and with IgG4-RD RI ≤9 at RTX treatment.

<p>IgG4-RD RI, IgG4-related disease Responder Index.</p

Risk of disease relapse following rituximab for patients with glucocorticoid and without glucocorticoid maintenance therapy at last follow-up or relapse.

<p>Risk of disease relapse following rituximab for patients with glucocorticoid and without glucocorticoid maintenance therapy at last follow-up or relapse.</p